$646 Million is the total value of Rock Springs Capital Management LP's 83 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | MERCK & CO INC NEW | $28,158,000 | +2.5% | 475,000 | 0.0% | 4.36% | -11.6% | |
| PRGO | PERRIGO CO PLC | $4,280,000 | +3.0% | 28,500 | 0.0% | 0.66% | -11.1% | |
| ICPT | INTERCEPT PHARMACEUTICALS IN | $3,574,000 | +0.0% | 15,100 | 0.0% | 0.55% | -13.7% | |
| WX | WUXI PHARMATECH CAYMAN INC | $3,379,000 | +6.6% | 96,500 | 0.0% | 0.52% | -8.1% | |
| VSAR | VERSARTIS INC | $2,360,000 | -32.3% | 124,255 | 0.0% | 0.36% | -41.6% | |
| ARWR | ARROWHEAD RESH CORP | $1,699,000 | +3.2% | 115,000 | 0.0% | 0.26% | -10.8% | |
| CERU | CERULEAN PHARMA INC | $361,000 | -27.4% | 85,635 | 0.0% | 0.06% | -37.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 43 | Q2 2024 | 4.0% |
| NEUROCRINE BIOSCIENCES INC | 42 | Q2 2024 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 42 | Q2 2024 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 42 | Q2 2024 | 2.4% |
| ACADIA HEALTHCARE COMPANY IN | 41 | Q2 2024 | 4.4% |
| ASCENDIS PHARMA A/S | 38 | Q2 2024 | 1.3% |
| BIOMARIN PHARMACEUTICAL INC | 38 | Q2 2024 | 1.3% |
| MACROGENICS INC | 38 | Q2 2024 | 0.5% |
| AMICUS THERAPEUTICS INC | 37 | Q2 2024 | 0.6% |
| ADAPTIMMUNE THERAPEUTICS PLC | 37 | Q2 2024 | 1.2% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Travere Therapeutics, Inc. | May 01, 2024 | 4,411,983 | 5.8% |
| Xilio Therapeutics, Inc. | April 05, 2024 | 3,003,259 | 8.7% |
| Aclaris Therapeutics, Inc. | February 14, 2024 | 2,998,495 | 4.2% |
| AGIOS PHARMACEUTICALS, INC. | February 14, 2024 | 2,152,173 | 3.8% |
| Gamida Cell Ltd.Sold out | February 14, 2024 | 0 | 0.0% |
| Immunocore Holdings plc | February 14, 2024 | 2,661,507 | 5.4% |
| Inozyme Pharma, Inc. | February 14, 2024 | 3,681,174 | 6.0% |
| Mereo BioPharma Group plc | February 14, 2024 | 39,919,255 | 5.7% |
| SPRUCE BIOSCIENCES, INC. | February 14, 2024 | 2,609,125 | 6.4% |
| Spyre Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.